Glucagon-like Peptide 1 Receptor Agonists in Cardio-Oncology: Pathophysiology of Cardiometabolic Outcomes in Cancer Patients
Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Irma Bisceglia(Azienda Ospedaliera San Camillo-Forlanini), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), I Giacobbe(University of Campania "Luigi Vanvitelli"), Domenico Gabrielli(Azienda Ospedaliera San Camillo-Forlanini), Massimiliano Berretta(University of Messina), Alessandro Inno(Ospedale Sacro Cuore Don Calabria), Stefano Oliva(Istituto Tumori Bari), Matteo Barbato(University of Milan), Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Tedeschi(Guglielmo da Saliceto Hospital), Marino Scherillo, Vienna Giordano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Laura Canale(Ospedale Versilia), Alessandra Greco(St. Catherine University)
Cited by 18
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Gut microbiota and cancer: How gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy
|Critical Reviews in Oncology/Hematology|2019|164
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105